Molecular endoscopy to predict response to vedolizumab therapy in ulcerative colitis (C02+)

我们建立了分子内镜作为一种有前途的新工具，预测生物治疗的反应，因为它前瞻性地分析了体内粘膜靶向表达和针对它的生物治疗的有效性之间的相关性。局部应用符合GMP的荧光抗体结合显微内镜导致靶细胞的可视化，我们进行了一项II期临床研究，以预测溃疡性结肠炎（UC）的抗TNF反应性。我们现在申请启动一项试验，以预测UC患者对Vedolizumab治疗的应答，因为这将进一步导致个体患者的个性化方法。

We established molecular endoscopy as a promising novel tool to predict responsiveness to biological therapies, as it prospectively analyses the correlation between in vivo mucosal target expression and effectiveness of a biological therapy directed against it. Topical application of a GMP-conform fluorescent antibody in conjunction with endomicroscopy led to the visualization of target cells, as we conducted a clinical phase II study to predict anti-TNF responsiveness in ulcerative colitis (UC). We now apply for initiation of a trial to predict response to vedolizumab treatment in UC patients, as this would further lead to a personalized approach in individual patients.